Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The developer of the AstraZeneca shot says the Delta variant has made herd immunity impossible because vaccinated people can still transmit the virus."
GLTA,
Farrell
https://news.yahoo.com/developer-astrazeneca-shot-says-delta-114837457.html
I afraid it is bad news for us. The Israeli and English delta variant data suggest the vaccines do not work as well as had been hoped plus we have many more unvaccinated here in the US compared to Israel and England. The unvaccinated are likely to have more severe infections, hospitalizations and death.
In addition we know the vaccinated can become infected at a relatively high rate even though they may have milder symptoms as a whole they are contagious with a high viral load; the Israeli experience indicates the vaccinated patients greater than 50 age are at risk for severe infections, pulmonary failure and death.
Unfortunately the delta variant experience in Israel and England is projecting a bleak picture here in the US for the next few weeks.The rising US Covid delta hospitalization rates and increasing ICU usage has already begun.
GLTA Farrell
Israel begins Pfizer boosters due to breakthrough infections.What if that does not work? Horrifying news.
When reviewing the statistics remember Israel's population is smaller than North Carolina's which has suffered about 3000 case per day the last few days
GLTA Farrell
"Almost 80 per cent of the adult {Israeli} population has been fully vaccinated, one of the highest rates in the world, but more than 6,000 people tested positive for Covid-19 on Monday, according to the health ministry. Nearly 650 people were in hospital and 400 of them were in serious condition, it said, without indicating how many had already been vaccinated."
"Just under 5 per cent of coronavirus tests were coming back positive, in a sign that the nation was in the midst of a major Covid increase, warned Salman Zarka, the government’s coronavirus tsar. Israel was at “a critical point for our health, for our lives and for our economy”, he said."
"Now, with studies showing the efficacy of the vaccine fading among the over-60s, some of whom received their first shots as early as December, health authorities have taken the lead in administering booster injections."
"Israel did not wait for the US Food and Drug Administration to approve boosters of the Pfizer vaccine, instead administering third shots to about 2,000 immunocompromised people weeks ago before extending it to all those over 60 on August 1. As many as 600,000 older Israelis have now received a third shot, which could soon be offered to the over-50s too."
"But the rapid pace of new infections makes it likely that new restrictions will have to be imposed, he said."
https://www.ft.com/content/9e06cb33-38a1-4efe-859e-95008c85a623
Thanks for sharing. The article and your comments add clarity to the discussion.
GLTA,Farrell
Below is a summary of an article from the New England Journal of Medicine:
"Antibodies induced by currently available mRNA vaccines can still neutralize the Delta and Kappa variants of the SARS-CoV-2 virus, but do so at a reduced potency, according to a report published in the New England Journal of Medicine.
The Delta variant, first identified in India and previously known as B.1.617.2, is now dominant in the United States. The Kappa variant, previously B.1.617.1, was also first identified in India.
Compared with the Washington strain that arrived in the United States last year, vaccine-induced antibodies are 2.9 times less able to neutralize Delta and 6.8 fold less able to neutralize Kappa. Still, researchers concluded that the antibodies induced by mRNA vaccines will be strong enough in many people and protective immunity is “most likely retained” against Delta and Kappa."
http://news.emory.edu/stories/2021/07/coronavirus_delta_kappa_vs_vaccine_antibodies/index.html
The real answer is we are not likely to know which is the best path for previously infected for some time. The current reports often conflict.
You have to agree the Delta variant is less responsive to antibody based therapies, Monoclonal antibodies, convalescent sera and vaccines than previous Covid viruses.
The most disturbing information is the break through infections seen in Israel and England where so many vaccinated individuals were hospitalized and died. Obviously the vaccinations are safer than the primary infections and confer lower hospitalization and death rates. Why is it the vaccines do not provide better protection?
Currently we do not have an adequate explanation for these illnesses. Is it because the vaccines lose potency with time.Obviously the variant mutations change the S protein structure and change its antigenic profile. Individuals differ in their immune responses. Does innate immunity produce a better T cell response?
This article discusses T cell immunity in vaccinated and in patients previously infected, but it also made this observation
"The ratio of serum virus neutralization GMT to recombinant RBD-binding IgG GMC is lower after immunization with BNT162b1 than after infection with SARS-CoV-2. As noted previously, this difference may be attributed, in part, to BNT162b1 eliciting antibodies that bind epitopes that are exposed on the RNA-encoded RBD immunogen but buried and inaccessible in the spikes of SARS-CoV-2 virions, differentially increasing RBD-binding IgG GMCs after immunization. In addition, infection with SARS-CoV-2 might elicit neutralizing antibodies that recognize epitopes that are exposed on virions and located outside the RBD, differentially increasing the serum neutralizing GMT after infection29,30.
https://www.nature.com/articles/s41586-020-2814-7
Good luck,
Farrell
It would make sense if IPIX made 2 billion a quarter. 8 billion a year opens a lot of doors.
Of course that seems impossible now just as it did for BioNTech in January of 2020.
GLTA Farrell
BioNTech is quite a company. Their primary source of income is from the Covid Vaccine, but they are involved in 80 clinical trials, many involve therapeutic vaccines against cancer.
https://clinicaltrials.gov/ct2/results?cond=&term=biontech&cntry=&state=&city=&dist=
If IPIX Brilacidin proves to be equally successful it would be interesting to see if they could expand the research on synthetic defensin mimetics. It is my understanding IPIX controls all the technical information and computer programs to make compounds similar to Brilacidin.
Perhaps they could merge with DeGrado's company,Pliant Therapeutics and engage some of the original Polymedixs researchers.
https://pliantrx.com/team/bill-degrado-ph-d/
I doubt that makes much business sense , but it would be great to develop new drugs with the background laid by Polymedixs.
GLTA Farrell
Israel, a highly vaccinated country,data shows 700 greater effect against delta with natural immunity than vaccine which was predominately Pfizer.
“With a total of 835,792 Israelis known to have recovered from the virus, the 72 instances of reinfection amount to 0.0086% of people who were already infected with COVID.
“By contrast, Israelis who were vaccinated were 6.72 times more likely to get infected after the shot than after natural infection, with over 3,000 of the 5,193,499, or 0.0578%, of Israelis who were vaccinated getting infected in the latest wave.”
With over 60% of their respective populations now fully vaccinated, Israel and the U.K. are perfect case studies demonstrating that vaccines are not playing the predominant role in slowing down the viral spread. If you compare all of the European countries by recent cases per million to vaccination rates, you will find zero correlation, and in fact, eastern European countries with low vaccination rates seem to have fewer cases.
https://newsrescue.com/delta-variant-natural-immunity-700-greater-protection-than-shot-data-from-israeli-govt-shows/
I looked for the royalty agreement and found the documents but the amounts were x'ed out. BioNtech's revenue was $2 billion the 1st quarter of 2021 up 7294.95%.
GLTA, Farrell
There exists conflicting research on this point, but I think Rand is right.
GLTA Farrell
Remdesivir was given an EUA at the interim report of its Phase 3 study. That's my best guess for Brilacin.
It could be sooner if the Phase 2 shows outstanding results, acing all the primary and secondary outcomes with absolute safety.
The other factor is the status of the pandemic. If the Delta virus outbreak continues to accelerate or if vaccine resistant or more deadly variants appear, Brilacidin could be pushed up to the drug of choice.
JMHO Farrell
Good point. It is a tremendous undertaking to manufacture ,distribute, market and sell a new drug flawlessly.
It is hard to imagine IPIX making the right personnel and business structural changes quickly enough to satisfy the demand of a new successful Covid drug. The key would be to find the pharmaceutical company to enter into a partnership or licensing agreement.
An example of a Covid pharmaceutical start up small partnering with a big Pharma for the reasons outlined above would be the Pfizer Bionet deal:
" Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021.
BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million."
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
If Brilacidin proves to be successful in the clinical trials the terms above are likely too conservative. Brilaciidin would be in a stage 3 trial with an EUA after the interim report at the earliest.
Good luck to all,
Farrell
Nice review. At this point IPIX should continue on its prudent course of carefully and thoughtfully engaging the FDA. An example of aggressive promotion drawing the ire of the FDA can be seen with Cytodyn.
The FDA's letter to Cytodyn was a warning to all pharma companies.
https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab
The fallout from the FDA slap down continues to plague the company. Last week Cytodyn received subpoenas from the SEC and DOJ regarding Leronlimab's promotion.
https://seekingalpha.com/news/3724193-cytodyn-receives-sec-doj-subpoenas-related-to-leronlimab-as-a-covid-19-treatment
The above is addition to lawsuits from class action attorneys and shareholders.
https://www.fiercebiotech.com/biotech/cytodyn-shares-plummet-after-being-accused-by-fda-cherry-picking-covid-19-data
https://www.cnbc.com/2021/07/24/large-shareholder-group-calls-for-a-board-overhaul-at-pharma-company-cytodyn.html
GLTA Farrell
Doomsday variant may be closer than you think. Brilacidin needed now.
https://www.newsweek.com/2021/08/13/doomsday-covid-variant-worse-delta-lambda-may-coming-scientists-say-1615874.html
Leo needs to hire the attorneys who wrote this contract.
Thanks for posting.
Farrell
Unbelievable. the CDC just blunders from one mistake to the next. The British Delta peak has past ,but they reported a reinfection rate of 40% .
The CDC thinks its OK to have over 100 million vaccinated people, many who believe they can not be reinfected and can not possibly spread the disease, not understand that there is a significant risk of reinfection and subsequent contagion.
GLTA Farrell
https://www.forbes.com/sites/joshuacohen/2021...it-matter/
There is a control SOC group with 60 pts and a treatment group of 60 pts with the SOC +Brilacidin.
THE FDA and others felt the study without SOC treatment for both groups was unethical. The Phase 3 study may have direct comparisons.
ACTI-6, a large trial with multiple repurposed drugs, has begun. It is possible Brilacidin will be a part of a future similar study if the phase 2 study is possible.
https://www.nih.gov/news-events/news-releases/large-clinical-trial-study-repurposed-drugs-treat-covid-19-symptoms.
GLTA Farrell
An enormous need exists for an effective Covid antiviral infections.
GLTA Farrell
The protocol does not call for the testing of mutations/variants. The delta variant became the dominant variant during the trial so many patients probably had the delta variant.
https://www.nytimes.com/2021/06/18/world/europe/coronavirus-russia-delta-moscow.html.
GLTA Farrell
Hopefully Brilacidin will also be given before they are sick, perhaps an aerosol or depo injection.
Time will tell.
GLTA Farrell
Herd immunity is not possible as long as the vaccinated can catch and spread the Delta variant. The powers that be understand that and the fact the public will vote them out if they can not stop the epidemic.
Local health care facilities have announced they are testing employees for Covid twice a week, both vaccinated and vaccinated. They understand vaccinated workers can catch and spread Covid19 variants.
Brilacidin may help stop the epidemic by treating Covid positives regardless of the vaccination status before they become super spreaders.
GLTA, Farrell
Great summary of the current research on Brilacidin's effects on Covid19 and its mutations. "different groups of Scientists" are there several labs studying Brilacidin now?
The PR is good news leading up to the release of Brilacidin Phase 2 study results soon.
GLTA Farrell
Vaccine proof variant "just a few mutations away" Dr Walensky
Brilacidin's EUA may be closer than I thought possible.
Dr Rochelle Walensky MD, CDC
The Centers for Disease Control and Prevention Director Rochelle Walensky, MD, MPH, made a dire prediction during a media briefing this week that, if we weren’t already living within the reality of the COVID-19 pandemic, would sound more like a pitch for a movie about a dystopian future.
Dr. Rochelle Walensky
“For the amount of virus circulating in this country right now largely among unvaccinated people, the largest concern that we in public health and science are worried about is that the virus … [becomes] a very transmissible virus that has the potential to evade our vaccines in terms of how it protects us from severe disease and death,” Dr. Walensky told reporters on July 27.
A new, more elusive variant could be “just a few mutations away,” she said.
GLTA, Farrell
https://www.mdedge.com/familymedicine/article/243682/coronavirus-updates/few-mutations-away-threat-vaccine-proof-variant?utm_medium=email&sso=true&utm_content=%E2%80%98A%20few%20mutations%20away%E2%80%99%3A%20The%20threat%20of%20a%20vaccine-proof%20variant&uac=144876AG&utm_source=News_MDedge_eNL_073021_F&ecd=wnl_new_210730_mdedge_8pm
Agree, Data base lock soon.
GLTA, Farrell
WAKEFIELD, MA – June 3, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Complete trial enrollment comprised 120 dosed patients recruited across multiple sites. Final data collection for the last patient enrolled in the study is expected to occur in early August (Study Day 60), which will then be followed by the process of unblinding study data and the reporting of topline study results.
“We are pleased to have reached this company milestone and particularly thank all of the participating investigator sites and patients, in addition to many others involved in supporting the completion of study enrollment, especially given the challenges brought on by the pandemic,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Encouraged by extensive laboratory-based Brilacidin antiviral research focused on coronaviruses, and building on previous pre-clinical and clinical results demonstrating a robust Brilacidin therapeutic profile, we prioritized the develop
Thanks the abstract will make a terrific PR next week.
Glta, Farrell
Phosphlipidosis requires intracelllular vesicle {also called lysosomes} formation to become manifest.The vesicles are the hallmark of both phosphlipidosis as well as possible drug resistance.The vesicles normally develop as a part of the manufacture and release of new viruses.
Just to review, Covid, like any virus circulates through the body and infects cells which takes several steps :
1. the viruses attach to cell walls or cell wall receptors ie ACE receptors
2.the viruses enter the cells
3.the viral m protein engages the cellular organelles, Golgi ribosomes etc to manufacture new viruses
4 The mature viruses are encased in vesicles {lysosomes] which attach to the inside of the cell wall and are released into the extracellular spaces where they can infect other cells and complete the process.
"Drug-induced phospholipidosis is a lysosomal storage disorder characterized by an intracellular excessive accumulation of phospholipids {in vesicles}. Its cellular mechanism is still not well understood, but it is known that cationic amphiphilic drugs can induce it. These drugs have a hydrophilic amine head group that can be protonated in the endolysosomal compartment...By compensating the negative surface charge, cationic enzymes are released from the surface of vesicles and proteolytically degraded, triggering a progressive lipid storage and the formation of inactive lamellar bodies...Drug-induced phospholipidosis (DIPL) is caused by long-term treatment of animals and humans with cationic amphiphilic drugs (CADs) leading to an intracellular accumulation of phospholipids in kidney, liver, lung, brain, cornea and other organs."
https://www.degruyter.com/document/doi/10.1515/hsz-2019-0270/html
Reasons it is unlikely Brilacidin could be associated with phosphlipidosis
1 The primary mechanism of action of Brilacidin is killing the virus in the extracellular space.
2. The secondary mechanism of action is Brilacidin prevents viral attachment to the cells.
3 Brilacidin prevents the virus from entering the cell by 2 mechanisms
4. Since it does not enter the cell the phospholipid vesicals or lysosomes will not be formed.
5.A computer modeling study suggested Brilacidin prevents expression of the viral M protein which again would prevent intracellular lysosome formation
6. Phosphlipidosis and Brilacidin drug resistance is prevented by 3 Brilacidin mechanisms of action
7.Phospholipidosis is associated with long term drug usage. Since Brilacidin will only be used 5 days at the most it is not likely to develop a lysosomal storage disorder in a short time period.
"brilacidin exhibits robust inhibition of SARS-CoV-2 in Vero cells and Calu-3 cells, and in two strains of the virus. Likely to function as a viral entry inhibitor [73,74,75], the proposed mechanism of action for brilacidin includes affecting the integrity of the viral membrane and interfering with viral entry."
https://www.mdpi.com/1999-4915/13/2/271/htm
Remember inherited lysosomal storage disorders in children take years or decades to become manifest.The best known example is Tay-Sachs disease where the young children are normal but they deteriorate with age.
https://www.degruyter.com/document/doi/10.1515/hsz-2019-0270/html
GLTA, Farrell
The military symposium for new anti viral therapies was supposed to include additional Brilacidin antiviral research. The presentation must be completed.
Hopefully the researchers at GMU will release the information and/or presentation in the near future.
GLTA, Farrell
It is interesting. I read the whole article.
The article proposes screening repurposed drugs for phospholipidoasis as a predictor of poor Covid 19 performance.
Since an antiviral has not been found to be effctive researchers could have screened for any biologic entity and would have come up with the same result.
Why is screening for phopholipidosis any different?
Is an obscure reference to phosphlipidosis pertinent to Brilacidin?
No, we are only days away from hearing the results of another group of patients being treated by Brilacidin. We do not need more in vitro testing when we are about to finish a clinical trial.
In Vitro testing for phospholipidosis has been available for decades.
Why doesn't the FDA mandate screening?.
GLTA,
Farrell
We need to add one more mechanism of action:
Cell type independent inhibition of primary lung fibroblasts.
The inhibition of lung fibroblast may help reduce the pulmonary complications of Covid19.
"BRILACIDIN was developed as a PLATFORM...with three mechanisms in one ANTIVIRAL, ANTIBACTERIAL, and ANTI-INFLAMMATORY...all in one.."
GLTA,
Farrell
https://static1.squarespace.com/static/5715352e20c647639137f992/t/60f98b02dee5a72cfce0c44e/1626966816579/GMU+ASV+2021+Brilacidin+talk+fv+7.21.21.pdf
If they do approve some there are others which will not be approved.
JMO Farrell
Here is a definition of a polymer from Britanica:
polymer, any of a class of natural or synthetic substances composed of very large molecules, called macromolecules, that are multiples of simpler chemical units called monomers. Polymers make up many of the materials in living organisms, including, for example, proteins, cellulose, and nucleic acids.Jun 8, 2021
Brilacidin does not contain repeating units or monomers. It is a small molecule made chemically of different smaller chemical components.
Polycide is a polymer. The monomer is the defensin mimetic which is linked multiple times to make the large molecule which allows it to be a large compound which can be used as a plastic like coating.
GLTA Farrell
Brilacidin is not polymer based even though Wikipedia says it is. Its structure is based on a defensin called Magainin, a short chain peptide defensin.discovered in the 80s by Dr Zassloff.
Dr DeGrado and Polymedix developed Brilacidin by chemically strengthening Magainin's chemical core with compounds called Arylamides which allowed improved durability as well as improved pharmacokinetics. Dr DeGrado and Polymedics further optimized its function using a super computer to guide small chemical changes in its structure to enhance its antibiotic abilities.
A diagram of Manginin and Brilacidin was part of this weeks AVS presentation.page 3.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/60f98b02dee5a72cfce0c44e/1626966816579/GMU+ASV+2021+Brilacidin+talk+fv+7.21.21.pdf
Actually Polymedix had success in developing a defensin mimetic polymer which they named Polycide. Polycide showed some ability as an antibiotic coating which could be used on a variety of products including surgical sutures. As far as I can tell IPIX still has the rights to Polycide.
https://www.globenewswire.com/news-release/2012/09/05/488925/16232/en/Data-Showing-Effectiveness-of-PolyCide-Antimicrobial-in-Surgical-Suture-Coatings-Published-in-American-Chemical-Society-Journal-Langmuir.html
Good luck, Farrell
I do not remember writing your quote but if I did I changed it to the one posted.
Best to ya,
Farrell
Yes, I agree you are correct. I apologize for any confusion my post created.
Some of my confusion was reading the article quickly and correlating the numerical description of the viruses with the early Washington and Italian variants. The following article helped me discern each. The Washington variant is called Wa1 and I had wrongly assumed it was the alpha variant since it was the first described in the US in Washington state. The Italian variant is called B1 and I thought it was the beta variant. The current CDC variants of concern are:The B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma)
When I quickly scanned the article Thursday morning I interpreted the summary sentence incorrectly.
https://science.sciencemag.org/content/370/6516/564
GLTA Farrell
Callmecrazy you are correct.
Great post. Brilacidin's market potential for UC, IBD, Covid and other viruses is potentially enormous. Approval for any one of these indications would be extremely profitable as well as providing beneficial treatments for diseases which poorly respond to current pharmaceuticals.
IMO Brilacidin has a very bright future.
GLTA Farrell
A drug resistant Candida auris outbreak has resulted in the CDC issuing a national warning about the infection and its potential to spread.
Polymedix did research with defensin mimetics similar to Brilacidin for Candida infections. I would be surprised if Fox chase is not pursing these studies further.
IPIX will receive 6% of all revenues if the research is successful.
https://www.cdc.gov/fungal/candida-auris/c-auris-drug-resistant.html
https://www.globenewswire.com/news-release/2020/07/22/2065754/0/en/Innovation-Pharmaceuticals-Grants-Licensing-Rights-to-Fox-Chase-Chemical-Diversity-Center-Inc-for-Antifungal-Technology.html
https://www.globenewswire.com/en/news-release/2012/01/20/465799/16232/en/PolyMedix-Defensin-Mimetic-Antimicrobial-Compounds-Show-Activity-Against-Oral-Candida-Fungus-and-Malaria.html
I think it does say it "Inhibition extends to different strains of SARS-CoV-2 (alpha, beta, gamma and delta strain"
It does not clarify what "assessments are planned".
It is a poorly written sentence which can fairly be read either way.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/60f98b02dee5a72cfce0c44e/1626966816579/GMU+ASV+2021+Brilacidin+talk+fv+7.21.21.pdf
Thanks for pointing that out.
GLTA Farrell
Bunyavirus is a large group of viruses with a number of different families and possibly hundreds of different species.
Rift Valley fever is not the only potentially fatal disorder associated with Bunyaviruses.
Bunyavirus infections are the causative agent in a number of serious human diseases.
Pneumonitis
-Hantavirus has a mortality rate of 35%
https://www.ecdc.europa.eu/en/hantavirus-infection/facts
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840873/
Hemorrhagic fever
-Rift valley fever
https://www.cdc.gov/vhf/rvf/about.html
-Lassa fever
https://www.who.int/health-topics/lassa-fever#tab=tab_1
Severe fever with thrombocytopenia syndrome (SFTS}
https://www.nature.com/articles/s12276-021-00610-1
Encephalitis
-California and LaCross encephalitis
https://emedicine.medscape.com/article/234159-overview
-Crimea-congo encephalitis
https://www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever
Almost all the disorders are uncommon, but so was chronavius at one point. Some have high fatality rates.We could be 1 mutation away from another viral pandemic. None has a specific therapeutic treatment.
GLTA Farrell
Breakthrough Covid 19 cases are occurring in the vaccinated.The Delta and especially the Lambda variant seem to producing breakthrough infections at a higher rate.
The more resistent Lambda variant is now in USA.It has 7 spike protein mutations. A new Gamma variant is reported in Chile with 11 mutations of the spike protein.
It is becoming apparent the Covid 19 is going to mutate frequently.The mutations change the Spike proteins which are the part of the virus vaccines, monoclonal antibodies and convalescent serum attack rendering the treatments less effective.
Therapeutics, like Brilacidin, will be invaluable in treating future Covid19.
https://www.infectioncontroltoday.com/view/lambda-variant-of-covid-19-might-be-resistant-to-vaccineshttps://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1.full
https://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1.full
From the CDC:
As of July 19, 2021, more than 161 million people in the United States had been fully vaccinated against COVID-19.
During the same time, CDC received reports from 49 U.S. states and territories of 5,914 patients with COVID-19 vaccine breakthrough infection who were hospitalized or died.
Total number of vaccine breakthrough infections reported to CDC
Hospitalized or fatal vaccine breakthrough cases reported to CDC 5,914
Female 2,881 (49%)
People aged ≥65 years 4,392 (74%)
Asymptomatic infections 1,164 (20%)
Hospitalizations* 5,601 (95%)
Deaths† 1,141 (19%)
*1,529 (27%) of 5,601 hospitalizations reported as asymptomatic or not related to COVID-19.
†292 (26%) of 1,141 fatal cases reported as asymptomatic or not related to COVID-19.
https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html
GLTA Farrell
Agreed, its all good. If phase2 is positive expect funding offers from multiple sources...DOD, NIH, pharma industry etc.
GLTA, Farrell